Mutations of METTL3 predict response to neoadjuvant chemotherapy in muscle-invasive bladder cancer

BACKGROUND AND AIM: Neoadjuvant chemotherapy (NAC) followed by radical cystectomy is the current gold standard treatment for muscle-invasive urothelial bladder cancer (MIBC). Nonetheless, some MIBC patients showed limited pathological response after NAC. Herein, we used whole-exome sequencing (WES) to identify genetic mutations in MIBC that can predict NAC response. METHODS: =20), respectively. ANNOVAR software was used to identify the potential mutations based on the data of WES. In addition, tumor-specific somatic mutations including single nucleotide variants and indels were called with the muTECT and Strelka software. The mutational analysis of specific genes was carried out based on the data from cBioPortal for Cancer Genomics. RESULTS: . CONCLUSION: can be a potential predictive biomarker of NAC response in MIBC patients. RELEVANCE FOR PATIENTS: is a potential biomarker for predicting response to NAC in MIBC patients, assisting doctors in making the clinical decision.